News


All series


All News

In a&nbsp;Targeted Oncology case-based peer perspectives live discussion, Heather A. Wakelee, MD, discussed treatment with tyrosine kinase inhibitor treatment options for a real-world Hispanic patient with EGFR-mutant non&ndash;small cell lung cancer.<br /> &nbsp;

The spread of COVID-19 has slowed down processes in many areas of health care, and there is widespread curiosity on how the pandemic will impact regulatory action in the United States. In the oncology community, providers and their patients await vital drugs that have been shown to approve upon survival and in some case are considered curative for different cancers.

In an open letter to the President of the United States, the Community Oncology Alliance brings attention to the critical needs of patients with cancer. Community Oncology Alliance requests all private health insurance companies immediately waive all &ldquo;prior authorization&rdquo; requirements for cancer treatments, which pose threat to cancer treatment, particularly in patients who are elderly and among the most vulnerable in the United States to contract COVID-19.

A significant percentage of younger men with high-risk prostate cancer who display minimal comorbidities continue to receive&nbsp;nondefinitive therapy (NDT), despite research that has demonstrated local therapy is more beneficial in this patient population, according to findings from a study published in&nbsp;<em>JAMA Oncology</em>&nbsp;show. A number of reasons for this have been identified, including&nbsp;&nbsp;insurance status and race/ethnicity.

Venetoclax in combination with azacytidine demonstrated a statistically significant improvement in overall survival and achieved a satisfactory composite complete remission rate in previously untreated patients with acute myeloid leukemia, meeting the co-primary end points of the phase III VIALE-A study. Genentech, the developer of venetoclax, announced the positive news in a press release, also noting that safety profiles of both drugs were consistent with prior reports.

As the COVID-19 pandemic evolves, healthcare providers in the oncology realm are faced with a number of unforeseen challenges requiring immediate attention and swift changes in policies. Experts at the Seattle Cancer Care Alliance shared their insights and advice with the public in a recent article to demonstrate how they have adapted to provide the most optimal care for patients with cancer in light of the COVID-19 outbreak.